Company Overview
Snapshot
Founded in July 2020 by Zev Brand, Sason Noama, and Avi (Avraham) Avital, Mindtension operates with 1–10 employees. The company has raised $5 million across three funding rounds. In January 2023, Mindtension secured $2 million in funding from Galia Kuts Family Office and Arazim Ltd.
Business overview
Mindtension is a Health Tech & Life Sciences company that develops an affordable, ultra-precise, rapid diagnostic platform for measuring signs of ADHD. Its core technology utilizes an electromyography (EMG) system to measure reflexive responses to auditory stimuli and inhibition levels, providing an objective assessment of attention deficit. This in-office diagnostic procedure enables therapists to immediately measure the effects of ADHD medication and adjust dosages. The company serves the healthcare industry, specifically targeting clinics and physicians, and operates within the medical devices, diagnostics devices, and mental health sectors, leveraging AI and machine learning.
Strategic signal
In November 2023, Mindtension, located near the Gaza border, faced significant challenges due to regional conflict, impacting its employees. Despite the trauma, the company remains committed to its mission and is actively pursuing FDA approval for its ADHD diagnostic device in the United States. This demonstrates resilience and a strong commitment to market expansion and regulatory milestones, signaling continued operational focus despite external adversities.
Log in to access full profile ›Company Intelligence Q&A
- What is Mindtension's core technology for ADHD diagnosis?
- Mindtension utilizes an electromyography (EMG) system to measure reflexive responses to auditory stimuli and levels of inhibition, providing an objective and rapid diagnostic platform for ADHD. This technology was developed based on 10 years of research at the Technion.
- What was a significant funding event for Mindtension?
- In January 2023, Mindtension raised $2 million in funding from Galia Kuts Family Office and Arazim Ltd. for its ADHD diagnosis and treatment tool.
- What is Mindtension's current status regarding FDA approval?
- Mindtension is actively working towards FDA approval for its ADHD diagnostic device in the United States. In January 2023, the company was conducting clinical trials in Southern Israel and the US, with plans to begin selling the device by the second half of 2024.
- How has recent geopolitical events impacted Mindtension?
- In November 2023, Mindtension's operations were affected by regional conflict near its offices in Kibbutz Nir Am, resulting in employee trauma and evacuations. Despite these challenges, the company has maintained its determination to continue working and pursue its goals.
- When was Mindtension founded and by whom?
- Mindtension was founded in July 2020 by Zev Brand, Sason Noama, and Avi (Avraham) Avital.